These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 18095779)

  • 1. An integrated approach: bisphosphonate management for the treatment of osteoporosis.
    Owens G; Jackson R; Lewiecki EM
    Am J Manag Care; 2007 Dec; 13 Suppl 11():S290-308; quiz S309-12. PubMed ID: 18095779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of bisphosphonate therapies for women with postmenopausal osteoporosis: implications of improved persistence with less frequently administered oral bisphosphonates.
    Earnshaw SR; Graham CN; Ettinger B; Amonkar MM; Lynch NO; Middelhoven H
    Curr Med Res Opin; 2007 Oct; 23(10):2517-29. PubMed ID: 17825128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of treatment efficacy and dosing frequency on cost-effectiveness of bisphosphonate treatment for osteoporosis: a perspective.
    Boonen S
    Curr Med Res Opin; 2009 Oct; 25(10):2335-41. PubMed ID: 19650755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [New development in bisphosphonate treatment. Clinical significance of combinatorial therapies with bisphosphonates and parathyroid hormone for osteoporosis].
    Takeuchi Y
    Clin Calcium; 2009 Jan; 19(1):85-90. PubMed ID: 19122268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cost-effectiveness of an RCT to establish whether 5 or 10 years of bisphosphonate treatment is the better duration for women with a prior fracture.
    Stevenson MD; Oakley JE; Lloyd Jones M; Brennan A; Compston JE; McCloskey EV; Selby PL
    Med Decis Making; 2009; 29(6):678-89. PubMed ID: 19509121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is treatment of early postmenopausal women with bisphosphonates justified?
    Epstein S
    Int J Clin Pract; 2007 Jun; 61(6):963-71. PubMed ID: 17504359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of osteoporosis medication beliefs and side-effect experiences on non-adherence to oral bisphosphonates.
    McHorney CA; Schousboe JT; Cline RR; Weiss TW
    Curr Med Res Opin; 2007 Dec; 23(12):3137-52. PubMed ID: 17988435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of adherence on lifetime fractures in osteoporotic women treated with daily and weekly bisphosphonates.
    Danese MD; Badamgarav E; Bauer DC
    J Bone Miner Res; 2009 Nov; 24(11):1819-26. PubMed ID: 19419313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Underdiagnosis and under-treatment of osteoporosis following fragility fracture.
    Aboyoussef M; Vierkoetter KR
    Hawaii Med J; 2007 Jul; 66(7):185-7. PubMed ID: 17879856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bisphosphonate dose and incidence of fractures in postmenopausal osteoporosis.
    Makras P; Hamdy NA; Zwinderman AH; Ballieux BE; Papapoulos SE
    Bone; 2009 May; 44(5):766-71. PubMed ID: 19442613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug insight: the use of bisphosphonates for the prevention and treatment of osteoporosis in men.
    Brown SA; Guise TA
    Nat Clin Pract Urol; 2007 Jun; 4(6):310-20. PubMed ID: 17551535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucocorticoid-induced osteoporosis.
    Berris KK; Repp AL; Kleerekoper M
    Curr Opin Endocrinol Diabetes Obes; 2007 Dec; 14(6):446-50. PubMed ID: 17982350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Refracture following fracture liaison service assessment illustrates the requirement for integrated falls and fracture services.
    Langridge CR; McQuillian C; Watson WS; Walker B; Mitchell L; Gallacher SJ
    Calcif Tissue Int; 2007 Aug; 81(2):85-91. PubMed ID: 17629737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prophylaxis of glucocorticoid-induced osteoporosis].
    Tanaka Y
    Clin Calcium; 2006 Nov; 16(11):1858-65. PubMed ID: 17079853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of osteoporosis in octogenarians].
    Pepersack T
    Rev Med Brux; 2008 Sep; 29(4):311-6. PubMed ID: 18949982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent developments in the management of postmenopausal osteoporosis with bisphosphonates: enhanced efficacy by enhanced compliance.
    Boonen S; Vanderschueren D; Venken K; Milisen K; Delforge M; Haentjens P
    J Intern Med; 2008 Oct; 264(4):315-32. PubMed ID: 18823505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Absolute risk for fracture and WHO guideline. Fall and fracture in elderly people : risk factors and strategies for prevention].
    Sugioka Y; Koike T;
    Clin Calcium; 2007 Jul; 17(7):1059-65. PubMed ID: 17607073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bisphosphonate therapy for osteoporosis: combining optimal fracture risk reduction with patient preference.
    Beard MK
    Curr Med Res Opin; 2012 Jan; 28(1):141-7. PubMed ID: 22103779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment with bisphosphonates: daily or once-weekly oral administration and intravenous injection].
    Kitahama S; Ishii T; Wada S
    Clin Calcium; 2005 Apr; 15(4):649-54. PubMed ID: 15802779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent developments in bisphosphonate therapy.
    Silverman SL; Maricic M
    Semin Arthritis Rheum; 2007 Aug; 37(1):1-12. PubMed ID: 17303219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.